KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Assets: 2010-2024

Historic Assets for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $303.9 million.

  • Nektar Therapeutics' Assets fell 2.15% to $301.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $301.3 million, marking a year-over-year decrease of 2.15%. This contributed to the annual value of $303.9 million for FY2024, which is 23.66% down from last year.
  • According to the latest figures from FY2024, Nektar Therapeutics' Assets is $303.9 million, which was down 23.66% from $398.0 million recorded in FY2023.
  • Over the past 5 years, Nektar Therapeutics' Assets peaked at $1.5 billion during FY2020, and registered a low of $303.9 million during FY2024.
  • Moreover, its 3-year median value for Assets was $398.0 million (2023), whereas its average is $470.8 million.
  • Data for Nektar Therapeutics' Assets shows a maximum YoY plummeted of 43.99% (in 2023) over the last 5 years.
  • Over the past 5 years, Nektar Therapeutics' Assets (Yearly) stood at $1.5 billion in 2020, then decreased by 27.40% to $1.1 billion in 2021, then crashed by 36.39% to $710.6 million in 2022, then crashed by 43.99% to $398.0 million in 2023, then declined by 23.66% to $303.9 million in 2024.